Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer

Rae Myers, Suzanne Greiner, Mary Harvey, Diane Soeffker, Marie Frenzke, Katalin Abraham, Alan Shaw, Shmuel Rozenblatt, Mark J Federspiel, Stephen J Russell, Kah-Whye Peng

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available. Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines, Moraten measles and Jeryl-Lynn mumps, in a murine model of intraperitoneal human ovarian cancer and compared their efficacies against a recombinant oncolytic measles virus (MV-CEA) that is being tested in a phase I clinical trial. The common feature of these viruses is that they express hemagglutinin and fusion therapeutic proteins that can induce extensive fusion of the infected cell with its neighbors, resulting in death of the cell monolayer. In vitro, the three viruses caused intercellular fusion in human ovarian cancer cells but with marked differences in fusion kinetics. MV-CEA was the fastest followed by Jeryl-Lynn mumps virus while Moraten measles virus was the slowest, although all viruses eventually caused comparable cell death 6 days postinfection. Tumor-bearing mice treated with 106 or 107 pfu (one thousand times the vaccine dose) of each of the three viruses responded favorably to therapy with significant prolongations in survival. All three viruses demonstrated equivalent antitumor potency. Commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents.

Original languageEnglish (US)
Pages (from-to)593-599
Number of pages7
JournalCancer Gene Therapy
Volume12
Issue number7
DOIs
StatePublished - Jul 2005

Fingerprint

Mumps Vaccine
Measles Vaccine
Active Immunotherapy
Ovarian Neoplasms
Viruses
Oncolytic Viruses
Measles virus
Measles
Cell Death
Mumps virus
Mumps
Attenuated Vaccines
Clinical Trials, Phase I
Cell Fusion
Hemagglutinins
Antineoplastic Agents
Neoplasms
Therapeutics
Vaccines
Survival

Keywords

  • Measles
  • Mumps
  • Ovarian cancer
  • Virotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. / Myers, Rae; Greiner, Suzanne; Harvey, Mary; Soeffker, Diane; Frenzke, Marie; Abraham, Katalin; Shaw, Alan; Rozenblatt, Shmuel; Federspiel, Mark J; Russell, Stephen J; Peng, Kah-Whye.

In: Cancer Gene Therapy, Vol. 12, No. 7, 07.2005, p. 593-599.

Research output: Contribution to journalArticle

Myers, R, Greiner, S, Harvey, M, Soeffker, D, Frenzke, M, Abraham, K, Shaw, A, Rozenblatt, S, Federspiel, MJ, Russell, SJ & Peng, K-W 2005, 'Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer', Cancer Gene Therapy, vol. 12, no. 7, pp. 593-599. https://doi.org/10.1038/sj.cgt.7700823
Myers R, Greiner S, Harvey M, Soeffker D, Frenzke M, Abraham K et al. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Therapy. 2005 Jul;12(7):593-599. https://doi.org/10.1038/sj.cgt.7700823
Myers, Rae ; Greiner, Suzanne ; Harvey, Mary ; Soeffker, Diane ; Frenzke, Marie ; Abraham, Katalin ; Shaw, Alan ; Rozenblatt, Shmuel ; Federspiel, Mark J ; Russell, Stephen J ; Peng, Kah-Whye. / Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. In: Cancer Gene Therapy. 2005 ; Vol. 12, No. 7. pp. 593-599.
@article{5b643942345a45b480b1997f70f6fa2a,
title = "Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer",
abstract = "Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available. Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines, Moraten measles and Jeryl-Lynn mumps, in a murine model of intraperitoneal human ovarian cancer and compared their efficacies against a recombinant oncolytic measles virus (MV-CEA) that is being tested in a phase I clinical trial. The common feature of these viruses is that they express hemagglutinin and fusion therapeutic proteins that can induce extensive fusion of the infected cell with its neighbors, resulting in death of the cell monolayer. In vitro, the three viruses caused intercellular fusion in human ovarian cancer cells but with marked differences in fusion kinetics. MV-CEA was the fastest followed by Jeryl-Lynn mumps virus while Moraten measles virus was the slowest, although all viruses eventually caused comparable cell death 6 days postinfection. Tumor-bearing mice treated with 106 or 107 pfu (one thousand times the vaccine dose) of each of the three viruses responded favorably to therapy with significant prolongations in survival. All three viruses demonstrated equivalent antitumor potency. Commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents.",
keywords = "Measles, Mumps, Ovarian cancer, Virotherapy",
author = "Rae Myers and Suzanne Greiner and Mary Harvey and Diane Soeffker and Marie Frenzke and Katalin Abraham and Alan Shaw and Shmuel Rozenblatt and Federspiel, {Mark J} and Russell, {Stephen J} and Kah-Whye Peng",
year = "2005",
month = "7",
doi = "10.1038/sj.cgt.7700823",
language = "English (US)",
volume = "12",
pages = "593--599",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer

AU - Myers, Rae

AU - Greiner, Suzanne

AU - Harvey, Mary

AU - Soeffker, Diane

AU - Frenzke, Marie

AU - Abraham, Katalin

AU - Shaw, Alan

AU - Rozenblatt, Shmuel

AU - Federspiel, Mark J

AU - Russell, Stephen J

AU - Peng, Kah-Whye

PY - 2005/7

Y1 - 2005/7

N2 - Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available. Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines, Moraten measles and Jeryl-Lynn mumps, in a murine model of intraperitoneal human ovarian cancer and compared their efficacies against a recombinant oncolytic measles virus (MV-CEA) that is being tested in a phase I clinical trial. The common feature of these viruses is that they express hemagglutinin and fusion therapeutic proteins that can induce extensive fusion of the infected cell with its neighbors, resulting in death of the cell monolayer. In vitro, the three viruses caused intercellular fusion in human ovarian cancer cells but with marked differences in fusion kinetics. MV-CEA was the fastest followed by Jeryl-Lynn mumps virus while Moraten measles virus was the slowest, although all viruses eventually caused comparable cell death 6 days postinfection. Tumor-bearing mice treated with 106 or 107 pfu (one thousand times the vaccine dose) of each of the three viruses responded favorably to therapy with significant prolongations in survival. All three viruses demonstrated equivalent antitumor potency. Commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents.

AB - Oncolytic viruses are promising cytoreductive agents for cancer treatment but extensive human testing will be required before they are made commercially available. Here, we investigated the oncolytic potential of two commercially available live attenuated vaccines, Moraten measles and Jeryl-Lynn mumps, in a murine model of intraperitoneal human ovarian cancer and compared their efficacies against a recombinant oncolytic measles virus (MV-CEA) that is being tested in a phase I clinical trial. The common feature of these viruses is that they express hemagglutinin and fusion therapeutic proteins that can induce extensive fusion of the infected cell with its neighbors, resulting in death of the cell monolayer. In vitro, the three viruses caused intercellular fusion in human ovarian cancer cells but with marked differences in fusion kinetics. MV-CEA was the fastest followed by Jeryl-Lynn mumps virus while Moraten measles virus was the slowest, although all viruses eventually caused comparable cell death 6 days postinfection. Tumor-bearing mice treated with 106 or 107 pfu (one thousand times the vaccine dose) of each of the three viruses responded favorably to therapy with significant prolongations in survival. All three viruses demonstrated equivalent antitumor potency. Commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents.

KW - Measles

KW - Mumps

KW - Ovarian cancer

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=22044447066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22044447066&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700823

DO - 10.1038/sj.cgt.7700823

M3 - Article

C2 - 15746945

AN - SCOPUS:22044447066

VL - 12

SP - 593

EP - 599

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 7

ER -